Methods of treating myeloproliferative disorders
AssigneeImpact Biomedicines, Inc.
InventorsTorsten Guenter Gerike, Aleksandra Rizo
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating a myeloproliferative disorder. In some aspects, the present disclosure provides methods of treating, stabilizing or lessening the severity or progression of one or more myeloproliferative disorders comprising administering to a patient previously treated with ruxolitinib a pharmaceutically acceptable composition comprising a compound of formula I, also known as fedratinib, or a pharmaceutically acceptable salt or hydrate thereof.
Claims25
A method of treating a myeloproliferative disorder, comprising administering to a patient previously treated with ruxolitinib Compound I
- or a pharmaceutically acceptable salt or hydrate thereof.
A method of reducing spleen volume by at least 25% in a patient suffering from or diagnosed with a myeloproliferative disorder comprising administering to a patient previously treated with ruxolitinib Compound I
- or a pharmaceutically acceptable salt or hydrate thereof.
A method of improving overall survival in a patient suffering from or diagnosed with a myeloproliferative disorder comprising administering to a patient previously treated with ruxolitinib Compound I
- or a pharmaceutically acceptable salt or hydrate thereof.
A method of improving symptom response rate in a patient suffering from or diagnosed with a myeloproliferative disorder comprising administering to a patient previously treated with ruxolitinib Compound I
- or a pharmaceutically acceptable salt or hydrate thereof.
A method of increasing the median survival in a patient population suffering from or diagnosed with a myeloproliferative disorder that has relapsed and/or is refractory to ruxolitinib comprising administering to a patient previously treated with ruxolitinib Compound I
- or a pharmaceutically acceptable salt or hydrate thereof.
A method of decreasing allele burden in a patient having a somatic mutation or clonal marker associated with or indicative of a myeloproliferative disorder comprising administering to a patient previously treated with ruxolitinib Compound I
- or a pharmaceutically acceptable salt or hydrate thereof.
Dependencies are inferred from the claim text.